All news
2022
Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of TAVNEOS® (avacopan) for ANCA-Associated Vasculitis
Montreal, Canada
April 14, 2022
Otsuka Canada Pharmaceutical Inc. announces Health Canada approval of TAVNEOS® (avacopan) for ANCA-Associated Vasculitis Health Canada approved the first orally-administered inhibitor of the complement 5a receptor – for the treatment of two types of ANCA-associated vasculitis (GPA and MPA), a debilitating disease with significant unmet medical needs Launch is expected in Canada in the […]
2021
Sunovion, Sumitomo Dainippon Pharma and Otsuka Enter Worldwide Development and Commercialization Collaboration
Marlborough, Mass., U.S. and Osaka and Tokyo, JAPAN
September 30, 2021
Sunovion Pharmaceuticals Inc. (Sunovion),its parent company Sumitomo Dainippon Pharma Co., Ltd. (Sumitomo Dainippon Pharma) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced today that the companies have entered into a worldwide license agreement for the joint development and commercialization of four compounds: ulotaront (SEP-363856), non-racemic ratio of amisulpride enantiomers (SEP-4199), SEP-378614 and SEP-380135.
2021
Health Canada Approves Otsuka and Lundbeck’s ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension) Alternative Initiation Regimen
Montreal
March 3, 2021
Otsuka Pharmaceutical Canada Inc. (Otsuka) and Lundbeck Canada Inc. (Lundbeck) announce that Health Canada issued a Notice of Compliance for an alternative initiation regimen for ABILIFY MAINTENA® (aripiprazole for prolonged release injectable suspension). Authorization for use of the alternative initiation regimen takes effect immediately.